ES2600879T3 - Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas - Google Patents

Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas Download PDF

Info

Publication number
ES2600879T3
ES2600879T3 ES10830777.8T ES10830777T ES2600879T3 ES 2600879 T3 ES2600879 T3 ES 2600879T3 ES 10830777 T ES10830777 T ES 10830777T ES 2600879 T3 ES2600879 T3 ES 2600879T3
Authority
ES
Spain
Prior art keywords
fvw
amino acid
acid sequence
kits
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10830777.8T
Other languages
English (en)
Inventor
Thomas Barnett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Therapeutics LLC
Original Assignee
Grifols Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Therapeutics LLC filed Critical Grifols Therapeutics LLC
Application granted granted Critical
Publication of ES2600879T3 publication Critical patent/ES2600879T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polipéptido que comprende una primera secuencia de aminoácidos presente en un polipéptido de FvW y una segunda secuencia de aminoácidos heteróloga con respecto a la primera, en el que dicho polipéptido es capaz de unirse a un FVIII y formar dímeros, oligómeros y multímeros, con la condición de que el polipéptido carezca, como mínimo, de los dominios D4, B1, B2, B3, C1, C2 y CK del FvW, en el que la segunda secuencia de aminoácidos corresponde a una inmunoglobulion Fc, en el que la segunda secuencia de aminoácidos es un extremo carboxiterminal con respecto a la primera secuencia de aminoácidos, y en el que la primera secuencia de aminoácidos es tal como se indica en SEC ID NO:11, SEC ID NO:13 o SEC ID NO:15.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22

Claims (1)

  1. imagen1
ES10830777.8T 2009-11-13 2010-11-12 Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas Active ES2600879T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US261145P 2001-01-12
US26114509P 2009-11-13 2009-11-13
PCT/US2010/056496 WO2011060242A2 (en) 2009-11-13 2010-11-12 Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto

Publications (1)

Publication Number Publication Date
ES2600879T3 true ES2600879T3 (es) 2017-02-13

Family

ID=43992414

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10830777.8T Active ES2600879T3 (es) 2009-11-13 2010-11-12 Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas

Country Status (20)

Country Link
US (1) US8759293B2 (es)
EP (1) EP2499165B1 (es)
JP (1) JP5876416B2 (es)
KR (1) KR101808751B1 (es)
CN (1) CN102648212B (es)
AU (1) AU2010319425B2 (es)
BR (1) BR112012011740A2 (es)
CA (1) CA2780542C (es)
CL (1) CL2012001258A1 (es)
ES (1) ES2600879T3 (es)
HK (1) HK1170244A1 (es)
HU (1) HUE029454T2 (es)
IL (1) IL219679A (es)
MX (1) MX2012005527A (es)
NZ (1) NZ600278A (es)
PL (1) PL2499165T3 (es)
PT (1) PT2499165T (es)
RU (1) RU2579977C2 (es)
WO (1) WO2011060242A2 (es)
ZA (1) ZA201203795B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
CA2688490C (en) 2007-06-01 2022-06-21 Scott E. Strome Immunoglobulin constant region fc receptor binding agents
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
HUE029454T2 (en) 2009-11-13 2017-03-28 Grifols Therapeutics Inc Von Willebrand Factor (VWF) -containing preparations and related procedures, kits and applications
DK2598533T3 (en) 2010-07-28 2019-04-23 Gliknik Inc Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions
WO2013098676A1 (en) 2011-12-30 2013-07-04 Grifols, S.A. Method for purifying factor viii
PL2804623T3 (pl) * 2012-01-12 2020-03-31 Bioverativ Therapeutics Inc. Chimeryczne polipeptydy czynnika viii i ich zastosowania
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
EP3549953A1 (en) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
CA2864904C (en) 2012-02-15 2023-04-25 Amunix Operating Inc. Factor viii compositions and methods of making and using same
CN104411716B (zh) 2012-04-24 2018-09-07 诺和诺德股份有限公司 适用于治疗血友病的化合物
KR102329315B1 (ko) 2012-07-11 2021-11-19 바이오버라티브 테라퓨틱스 인크. Xten 및 폰 빌레브란트 인자 단백질과의 viii 인자 복합체 및 이의 용도
MX2015002269A (es) 2012-08-20 2015-07-06 Gliknik Inc Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente.
CA2888982C (en) 2012-10-24 2020-07-21 Platelet Targeted Therapeutics, Llc Platelet targeted treatment
GB201304973D0 (en) * 2013-03-19 2013-05-01 Profactor Pharma Ltd Recombinant protein
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
EP3008084A2 (en) * 2013-06-12 2016-04-20 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
WO2014210547A1 (en) * 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker
EP3013358A4 (en) * 2013-06-28 2017-03-22 Biogen MA Inc. Thrombin cleavable linker with xten and its uses thereof
WO2015021423A2 (en) * 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
CN106456718A (zh) * 2014-01-10 2017-02-22 比奥根Ma公司 因子viii嵌合蛋白及其用途
US10626164B2 (en) * 2014-07-25 2020-04-21 Csl Limited Purification of VWF
US9701933B2 (en) * 2014-09-19 2017-07-11 Sarfaraz K. Niazi Harvesting and purification or perfusion yielder (HAPPY) device
SG11201706659WA (en) * 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
ES2912300T3 (es) 2015-05-22 2022-05-25 CSL Behring Lengnau AG Procedimientos de preparación de factor von Willebrand modificado
JP6573989B2 (ja) 2015-05-22 2019-09-11 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
SG10201912498YA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated truncated von willebrand factor
US10808023B2 (en) 2016-01-07 2020-10-20 CSL Behring Lengnau AG Mutated von Willebrand factor
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
EP3476937A4 (en) 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
WO2018087271A1 (en) 2016-11-11 2018-05-17 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
CA3043250A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
WO2018107079A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
CN111132693A (zh) * 2017-04-20 2020-05-08 芝加哥大学 用与免疫治疗抗体连接的ecm亲和肽治疗癌症的方法和组合物
GB201707139D0 (en) * 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides
BR112019026743A2 (pt) 2017-06-22 2020-06-30 CSL Behring Lengnau AG modulação da imunogenicidade de fviii através de vwf truncado
AU2018298232A1 (en) * 2017-07-07 2020-01-30 Takeda Pharmaceutical Company Limited Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant VWF
CA3081106A1 (en) * 2017-11-01 2019-05-09 Queen's University At Kingston Von willebrand factor proteins for treating bleeding disorders
US10654911B1 (en) * 2019-04-02 2020-05-19 Beijing Neoletix Biological Technology Co., Ltd. Vector co-expressing truncated von Willebrand factor and factor VIII
JP2022538357A (ja) 2019-07-04 2022-09-01 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ＶＩＩＩ凝固因子のｉｎ ｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ）
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2024106355A1 (ja) * 2022-11-14 2024-05-23 セルジェンテック株式会社 血液凝固第ｖｉｉｉ因子改変体を産生するエクスビボ遺伝子治療用細胞

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234991A (en) 1975-07-29 1993-08-10 Pasteur Merieux Serums And Vaccines Porous mineral support coated with an aminated polysaccharide polymer
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5149637A (en) 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
FR2616437B1 (fr) 1987-06-11 1990-09-07 Ibf Polymeres composites, leur preparation et leur utilisation en chromatographie liquide
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5683912A (en) 1994-07-21 1997-11-04 The Salk Institute For Biological Studies Cloning and expression of a novel acetylcholine-gated ion channel receptor subunit
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
AU2253392A (en) * 1991-06-20 1993-01-25 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic fragments of von willebrand factor
DE4204694C3 (de) * 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5268097A (en) 1992-06-19 1993-12-07 Sepracor Inc. Passivated and stabilized porous mineral oxide supports and method for the preparation and use of same
WO1994011384A1 (en) 1992-11-13 1994-05-26 Immunex Corporation Novel cytokine designated elk ligand
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US5849989A (en) 1994-10-07 1998-12-15 Ontogeny, Inc. Insulin promoter factor, and uses related thereto
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
ATE425175T1 (de) 1996-01-23 2009-03-15 Operon Biotechnologies Inc Verfahren und zusammensetzungen zur bestimmung von sequenzen von nukleinsäure-molekülen
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
AT403765B (de) 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
DE69734247T2 (de) 1996-07-19 2006-06-22 The Regents Of The University Of Michigan, Ann Arbor Für den von willebrand faktor der hunde kodierende dna und verfahren zu ihrer verwendung
US6074832A (en) 1996-07-19 2000-06-13 The Regents Of The University Of Michigan DNA encoding canine von Willebrand factor and methods of use
US6063593A (en) 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
SI0950067T1 (sl) 1996-11-27 2007-12-31 Genentech Inc Afinitetno čiščenje polipeptida na proteinskemA matriksu
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
WO1998042753A1 (en) 1997-03-27 1998-10-01 Trustees Of Boston University Novel antiplatelet agent
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
HUP0002518A3 (en) 1997-07-22 2003-01-28 Qiagen Genomics Inc Computer method and system for correlating sequencing data by ms
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE59914490D1 (de) 1998-11-10 2007-10-18 Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
US7144996B1 (en) 1999-03-05 2006-12-05 Genentech, Inc. Nucleic acid encoding human suppressor of fused
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US20050164386A1 (en) 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US20060099685A1 (en) 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
CA2921260A1 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2001094366A1 (en) 2000-06-02 2001-12-13 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US20050153383A1 (en) 2000-07-28 2005-07-14 Montgomery Robert R. Synthetic and recombinant substrates for the detecion of the von willebrand factor-cleaving protease
AUPR278301A0 (en) 2001-01-31 2001-02-22 Bionomics Limited A novel gene
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
AU2002341746A1 (en) 2001-09-18 2003-04-01 Avigenics, Inc. Production of a transgenic avian by cytoplasmic injection
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
WO2003047507A2 (en) 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
AU2002357249A1 (en) 2001-12-13 2003-07-09 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2492267C (en) 2002-07-15 2013-09-10 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
ES2361036T3 (es) * 2003-05-06 2011-06-13 Syntonix Pharmaceuticals, Inc. Proteínas quiméricas vii-fc del factor de coagulación para el tratamiento de un trastorno hemostático.
JP2005073528A (ja) * 2003-08-28 2005-03-24 Genetics Inst Llc 生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP3184551A1 (en) 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialic acid derivatives
EP1791557A4 (en) 2004-09-07 2009-09-23 Archemix Corp MEDICAL CHEMISTRY USING APTAMERS
GB0423974D0 (en) * 2004-10-28 2004-12-01 Ares Trading Sa Proteins
DK1835938T3 (da) * 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
SI1836500T1 (sl) 2005-01-14 2010-11-30 Ablynx Nv Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007102946A2 (en) * 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
SG172692A1 (en) 2006-06-12 2011-07-28 Symphogen As Pan-cell surface receptor- specific therapeutics
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
EP3231440A1 (en) * 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
US8114633B2 (en) 2007-12-27 2012-02-14 Baxter International Inc. Methods for differentiating plasma-derived protein from recombinant protein in a sample
TW201731488A (zh) 2007-12-28 2017-09-16 巴克斯歐塔公司 重組ｖｗｆ調配物
JP5832285B2 (ja) * 2008-06-24 2015-12-16 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 延長されたインビボ半減期を有する第ｖｉｉｉ因子、フォン・ヴィレブランド因子又はそれらの複合体
JP2012500250A (ja) 2008-08-21 2012-01-05 オクタファルマ アクチェン ゲゼルシャフト 組換えにより産生したヒト第ｖｉｉｉ及び第ｉｘ因子
US20110086362A1 (en) 2009-10-09 2011-04-14 Massachusetts Institute Of Technology High-Throughput Method for Quantifying Sialylation of Glycoproteins
HUE029454T2 (en) 2009-11-13 2017-03-28 Grifols Therapeutics Inc Von Willebrand Factor (VWF) -containing preparations and related procedures, kits and applications

Also Published As

Publication number Publication date
WO2011060242A2 (en) 2011-05-19
EP2499165B1 (en) 2016-09-14
NZ600278A (en) 2014-04-30
JP2013510581A (ja) 2013-03-28
JP5876416B2 (ja) 2016-03-02
RU2579977C2 (ru) 2016-04-10
EP2499165A2 (en) 2012-09-19
US20120289468A1 (en) 2012-11-15
CN102648212B (zh) 2014-12-03
HK1170244A1 (zh) 2013-02-22
ZA201203795B (en) 2014-10-29
CL2012001258A1 (es) 2012-09-14
KR20120113214A (ko) 2012-10-12
PL2499165T3 (pl) 2017-04-28
HUE029454T2 (en) 2017-03-28
EP2499165A4 (en) 2013-09-11
RU2012122402A (ru) 2013-12-20
PT2499165T (pt) 2016-10-28
CA2780542A1 (en) 2011-05-19
CN102648212A (zh) 2012-08-22
MX2012005527A (es) 2012-08-08
IL219679A (en) 2016-11-30
AU2010319425A1 (en) 2012-06-14
CA2780542C (en) 2020-03-24
IL219679A0 (en) 2012-07-31
BR112012011740A2 (pt) 2018-03-27
KR101808751B1 (ko) 2017-12-13
AU2010319425B2 (en) 2015-07-02
US8759293B2 (en) 2014-06-24
WO2011060242A3 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
ES2600879T3 (es) Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas
ES2563091T3 (es) Polipéptidos modificados genéticamente que tienen duración de acción potenciada
CO6210757A2 (es) Proeina de fusion que comprende prame o un fragmento inmunogenico del mismo
ES2602971T3 (es) Composición de anticuerpo modificado
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
EA201691669A1 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
ES2586418T3 (es) Vacuna de proteína de fusión
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
CO7170123A2 (es) Complejo del factor viii con xten y proteína del factor von willebrand y sus usos
PE20181206A1 (es) Construcciones especificas del higado, casetes de expresion del factor viii y metodos de uso de estos
BR112014019901A2 (pt) proteínas de fator viii recombinante
CR10591A (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
ES2513716T3 (es) Enzimas lecitina-colesteros acitransferasa modificadas
JP2013172734A5 (es)
ES2676499T3 (es) Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
AR092076A1 (es) Proteinas homodimericas
AR089324A1 (es) Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas
AR083454A1 (es) Antigeno de citomegalovirus
EA201401211A1 (ru) Улучшенные варианты фермента химозина
ES2666720T3 (es) Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt
NZ586074A (en) LCLRP peptides, constructs and uses thereof